ECSP11011311A - Composiciones y metodos para terapia prolongada con aminopiridinas - Google Patents

Composiciones y metodos para terapia prolongada con aminopiridinas

Info

Publication number
ECSP11011311A
ECSP11011311A EC2011011311A ECSP11011311A ECSP11011311A EC SP11011311 A ECSP11011311 A EC SP11011311A EC 2011011311 A EC2011011311 A EC 2011011311A EC SP11011311 A ECSP11011311 A EC SP11011311A EC SP11011311 A ECSP11011311 A EC SP11011311A
Authority
EC
Ecuador
Prior art keywords
methods
compositions
aminopiridins
prolonged therapy
prolonged
Prior art date
Application number
EC2011011311A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Blight
Ron Cohen
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011311(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of ECSP11011311A publication Critical patent/ECSP11011311A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EC2011011311A 2009-02-11 2011-09-08 Composiciones y metodos para terapia prolongada con aminopiridinas ECSP11011311A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15167909P 2009-02-11 2009-02-11
US25956309P 2009-11-09 2009-11-09
US28587209P 2009-12-11 2009-12-11
US28895309P 2009-12-22 2009-12-22
US29925910P 2010-01-28 2010-01-28

Publications (1)

Publication Number Publication Date
ECSP11011311A true ECSP11011311A (es) 2011-10-31

Family

ID=42562065

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011311A ECSP11011311A (es) 2009-02-11 2011-09-08 Composiciones y metodos para terapia prolongada con aminopiridinas

Country Status (22)

Country Link
US (3) US20120029035A1 (OSRAM)
JP (1) JP2012517449A (OSRAM)
KR (3) KR20170034452A (OSRAM)
CN (2) CN102046174A (OSRAM)
AR (1) AR075413A1 (OSRAM)
AU (2) AU2010213663A1 (OSRAM)
BR (2) BRPI1000030A2 (OSRAM)
CA (1) CA2751581A1 (OSRAM)
CL (1) CL2011001927A1 (OSRAM)
CO (1) CO6440534A2 (OSRAM)
EA (1) EA022755B1 (OSRAM)
EC (1) ECSP11011311A (OSRAM)
IL (1) IL214500A0 (OSRAM)
MX (1) MX2011008485A (OSRAM)
NI (1) NI201100155A (OSRAM)
NZ (1) NZ595046A (OSRAM)
PE (1) PE20120791A1 (OSRAM)
SG (2) SG10201609184PA (OSRAM)
TN (1) TN2011000403A1 (OSRAM)
TW (2) TW201032809A (OSRAM)
UY (2) UY32444A (OSRAM)
WO (2) WO2010093838A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20150111930A1 (en) * 2013-10-23 2015-04-23 Afgin Pharma, Llc Topical regional neuro-affective therapy
TW201125562A (en) * 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
CN102442942A (zh) * 2010-10-08 2012-05-09 天津和美生物技术有限公司 4-氨基吡啶的多晶型物及其制备和应用
EP2995305B1 (en) * 2011-01-28 2020-03-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
EP3381455A1 (en) * 2012-02-13 2018-10-03 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
WO2014028387A1 (en) * 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
EP3103096A4 (en) * 2014-02-04 2018-01-03 Optimata Ltd. Method and system for prediction of medical treatment effect
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
WO2022124946A1 (ru) * 2020-12-10 2022-06-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые полиморфные формы 4-аминопиридина и их фармацевтическое применение
CN112914884B (zh) * 2021-01-19 2022-02-11 重庆火后草科技有限公司 通过稳态时长置信度测量睡眠状态下的体重值的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US6288026B1 (en) * 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions

Also Published As

Publication number Publication date
TW201032809A (en) 2010-09-16
WO2010093838A1 (en) 2010-08-19
PE20120791A1 (es) 2012-07-08
TW201034665A (en) 2010-10-01
KR20120000560A (ko) 2012-01-02
MX2011008485A (es) 2011-11-04
EA022755B1 (ru) 2016-02-29
NZ595046A (en) 2013-10-25
US20150313886A1 (en) 2015-11-05
AU2016219650B2 (en) 2018-05-10
AU2016219650C1 (en) 2018-08-23
UY32444A (es) 2010-09-30
SG173641A1 (en) 2011-09-29
UY32445A (es) 2010-09-30
AR075413A1 (es) 2011-03-30
AU2010213663A1 (en) 2011-09-29
NI201100155A (es) 2012-02-16
KR20170034452A (ko) 2017-03-28
CN101896182A (zh) 2010-11-24
KR20180114250A (ko) 2018-10-17
CO6440534A2 (es) 2012-05-15
EA201171043A1 (ru) 2012-02-28
WO2010093839A1 (en) 2010-08-19
CL2011001927A1 (es) 2012-07-20
SG10201609184PA (en) 2016-12-29
BRPI1000030A2 (pt) 2018-02-14
TN2011000403A1 (en) 2013-03-27
JP2012517449A (ja) 2012-08-02
US20120029035A1 (en) 2012-02-02
CA2751581A1 (en) 2010-08-19
AU2016219650A1 (en) 2016-09-15
IL214500A0 (en) 2011-09-27
US20170319562A1 (en) 2017-11-09
BRPI1000031A2 (pt) 2018-02-14
CN102046174A (zh) 2011-05-04

Similar Documents

Publication Publication Date Title
CO6440534A2 (es) Composiciones y métodos para terapia prolongada con aminopiridinas
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
PE20141792A1 (es) Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2014000517A1 (es) Compuestos derivados de heterociclos nitrogenados condensados, moduladores de pi3k; composicion farmaceutica; y uso en el tratamiento de una enfermedad tal como asma, lupus, osteoartritis, esclerosis multiple, cancer, entre otras.
PL3321355T3 (pl) Sposoby i kompozycje do klinicznego pozyskiwania komórek alogenicznych oraz zastosowania terapeutyczne
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
PH12013501707A1 (en) Mesogen-containing compounds
IN2015DN01119A (OSRAM)
ECSP18010481A (es) Composiciones de plinabulina
IN2014DN06104A (OSRAM)
CL2014002386A1 (es) Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras.
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
PH12015502118A1 (en) Pyridin-4-yl derivatives
IN2014DN03298A (OSRAM)
AR078323A1 (es) Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple
CO6761366A2 (es) Composiciones farmacéuticas para el tratamiento de glioma maligno
GT201400042A (es) Compuesto de benzotiazolona
CL2013001445A1 (es) Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer.
AR088764A1 (es) Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia